Related Experiment Video

Updated: Aug 21, 2026

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

NO-generating compounds modify tumoritoxic effect of doxorubicin

I V Kondakova1, G V Zagrebel'naya, E Ts Choinzonov

  • 1Institute of Oncology, Tomsk Research Center, Siberian Division of Russian Academy of Medical Sciences. oncology@info.tsu.ru

Bulletin of Experimental Biology and Medicine
|September 30, 2004
PubMed

Insights

Nitric oxide (NO) donors reduce doxorubicin's tumor-killing ability by increasing cancer cell DNA synthesis and decreasing apoptosis. This suggests NO protects tumor cell DNA from doxorubicin damage.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Doxorubicin is a widely used chemotherapy agent.
  • Nitric oxide (NO) plays complex roles in cancer biology.
  • Understanding drug-resistance mechanisms is crucial for effective cancer therapy.

Purpose of the Study:

  • To investigate the impact of nitric oxide (NO)-generating compounds on the efficacy of doxorubicin.
  • To determine if NO influences doxorubicin's cytotoxic effects on cancer cells.
  • To elucidate the mechanisms underlying NO's interaction with doxorubicin.

Main Methods:

  • In vitro evaluation of Ehrlich adenocarcinoma cells.
  • Assessment of DNA synthesis rates.
  • Quantification of apoptotic cell death.
  • Treatment with doxorubicin and NO-donating compounds.

Main Results:

  • NO donors significantly inhibited the tumoritoxic effect of doxorubicin.
  • Activation of DNA synthesis was observed in the presence of NO donors.
  • A decrease in doxorubicin-induced apoptosis was noted.
  • NO appears to protect tumor cell DNA from doxorubicin.

Conclusions:

  • Nitric oxide (NO) can antagonize the cytotoxic effects of doxorubicin in cancer cells.
  • NO may confer resistance to doxorubicin by preserving tumor cell DNA integrity.
  • Further research is warranted to explore NO modulation in chemotherapy regimens.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...